2017 PD THERAPEUTICS CONFERENCE

The Michael J. Fox Foundation for Parkinson’s Research
11th Annual Parkinson’s Disease Therapeutics Conference
October 30, 2017
New York, NY

POSTER SESSION ON NOVEL THERAPEUTIC TARGETS AND TOOLS

ALFONSO FASANO, MD, PhD
University of Toronto, Toronto Western Hospital
“Levodopa Versus Dopamine Agonist after Deep Brain Stimulation in Parkinson’s”

VERONICA FRANCARDO, PhD
Lund University
“ANAVEX 2-73, A Clinical Alzheimer Drug Candidate, Induces Neurorestoration in Experimental Parkinsonism”

VALERIE HINDIE, PhD
Caprion Inc.
“Parkinson’s Disease Biomarker Discovery and Verification Using Multiple Reaction Monitoring”

SEBASTIAN KADENER, PhD
Brandeis University
“Circular RNAs (circRNAs) as New Biomarkers of sParkinson Disease”

BERKLEY LYNCH, PhD
Rodin Therapeutics
“Safe, Selective HDAC Inhibitors for the Treatment of Synaptic Deficits in Neurodegeneration”

JARROD MARTO, PhD
Dana-Farber Cancer Institute
“DEEP-SEQ Mass Spectrometry Analysis of BioFIND CSF for Protein Abundance and Post-translational Modifications”

KALPANA MERCHANT, PhD
Transthera Consulting Co.

BRIAN FISKE, PhD
The Michael J. Fox Foundation for Parkinson’s Research
“A Pharmacokinetic Study of Oral Nilotinib in the Dog to Assess Partitioning into the Cerebrospinal Fluid and Brain”

IRA SHOULSON, MD
Georgetown University
“Foundations for a Patient-Reported Natural History of Parkinson Disease: Cross-sectional Analysis of the MJFF Fox Inisght Platform”

JEAN-MARC TAYMANS, PhD/Ir
Jean-Pierre Aubert Research Center
“Analysis of Measures of LRRK2 as a Disease Biomarker for Parkinson’s Disease in Sporadic and LRRK2 PD, a LRRK2 Cohort Consortium Study”